找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Competition Law and Policy in the Japanese Pharmaceutical Sector; Akira Negishi,Masako Wakui,Naoko Mariyama Book 2022 The Editor(s) (if ap

[复制链接]
查看: 37414|回复: 52
发表于 2025-3-21 17:34:19 | 显示全部楼层 |阅读模式
书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector
编辑Akira Negishi,Masako Wakui,Naoko Mariyama
视频videohttp://file.papertrans.cn/232/231141/231141.mp4
概述Provides a comprehensive guide to the Japanese pharmaceutical industry, focusing on competition law and policy.Examines the Japanese pharmaceutical sector, including competition, intellectual property
丛书名称Kobe University Monograph Series in Social Science Research
图书封面Titlebook: Competition Law and Policy in the Japanese Pharmaceutical Sector;  Akira Negishi,Masako Wakui,Naoko Mariyama Book 2022 The Editor(s) (if ap
描述.This is the first book published that focuses on competition law and policy in the Japanese pharmaceutical sector. It consists of chapters written and edited by academics who research the industry from various perspectives, including economics, competition law, pharmaceutical regulations, and intellectual property law. ..Competition policies involving pharmaceutical products attract attention from academics and policymakers worldwide. The pharmaceutical industry is regulated by drug laws that vary from country to country and are affected by differing practices and industrial structures. The book begins by examining drug regulations and trade practices in the industry that are peculiar to Japan and its healthcare system. It then presents the Japanese Antimonopoly Act and cases involving it, and discussions of current competition law issues in the Japanese pharmaceutical industry. The book also discusses innovation and intellectual property and economic analyses of pharmaceutical regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States...Japan is one of the biggest pharmaceutical markets in
出版日期Book 2022
关键词Antitrust law; Competition law; Pharmaceutical regulations; Antimonopoly; Intellectual property; Patent; M
版次1
doihttps://doi.org/10.1007/978-981-16-7814-1
isbn_softcover978-981-16-7816-5
isbn_ebook978-981-16-7814-1Series ISSN 2524-504X Series E-ISSN 2524-5058
issn_series 2524-504X
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapor
The information of publication is updating

书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector影响因子(影响力)




书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector影响因子(影响力)学科排名




书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector网络公开度




书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector网络公开度学科排名




书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector被引频次




书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector被引频次学科排名




书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector年度引用




书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector年度引用学科排名




书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector读者反馈




书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector读者反馈学科排名




单选投票, 共有 1 人参与投票
 

1票 100.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 21:57:07 | 显示全部楼层
发表于 2025-3-22 03:16:31 | 显示全部楼层
Competition and Cooperation: Building a Sustainable Healthcare Delivery System in a Society with a Dompetition policy. It then reviews the challenges the system faces. The chapter concludes by discussing the issues to be considered further when creating a sustainable healthcare delivery system and enacting competition policies.
发表于 2025-3-22 07:00:39 | 显示全部楼层
Drug Regulation in Japan held liable arises. A remedial system for health damage caused by the proper use of medicinal products also exists. Although remedies are not limited to damage caused by unknown side effects, a certain set of requirements, different from that for civil liability, must be met to for the plaintiff to
发表于 2025-3-22 09:42:08 | 显示全部楼层
发表于 2025-3-22 14:05:04 | 显示全部楼层
发表于 2025-3-22 19:45:32 | 显示全部楼层
发表于 2025-3-22 23:07:28 | 显示全部楼层
发表于 2025-3-23 01:47:01 | 显示全部楼层
发表于 2025-3-23 06:11:22 | 显示全部楼层
2524-504X cal regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States...Japan is one of the biggest pharmaceutical markets in978-981-16-7816-5978-981-16-7814-1Series ISSN 2524-504X Series E-ISSN 2524-5058
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 吾爱论文网 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
QQ|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-8-9 10:59
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表